Showing 621 - 640 results of 1,766 for search '(( 12 meet decrease ) OR ( 10 ((we decrease) OR (((a decrease) OR (mean decrease)))) ))*', query time: 0.15s Refine Results
  1. 621
  2. 622
  3. 623
  4. 624
  5. 625
  6. 626

    Pd nanocrystals encapsulated in MOF-derived Ni/N-doped hollow carbon nanosheets for efficient thermal CO oxidation: unveiling the effect of porosity by Ipadeola, Adewale K.

    Published 2023
    “…The obtained Pd/Ni-MOF-HNC possesses hollow carbon sheets with a great surface area (153.05 m2 g−1), pore volume (0.12 cm3 g−1), rich Pd/Ni-Nx active sites, Ni-metal defects, rich N-content (7.53 at%), mixed Pd/Ni-oxide phases, and uniformly distributed ultra-small Pd nanocrystals (7.03 ± 1.10 nm); meanwhile, Pd/Ni-MOF-NC formed without etching had no porosity and less Ni-metal defects. …”
    Get full text
    Get full text
    Get full text
  7. 627

    Wind energy potential along the onshore and offshore Qatar by Mohammed, Aboobacker Valliyil

    Published 2020
    “…cant increase or decrease of wind power around Qatar in the last 40 years in most of the locations, while there is a slight decreasing trend in the o?…”
    Get full text
    Get full text
  8. 628
  9. 629
  10. 630
  11. 631
  12. 632
  13. 633

    Dispatchable capacity optimization strategy for battery swapping and charging station aggregators to participate in grid operations by Mingze, Zhang

    Published 2023
    “…Also, the aggregator does not worsen the original power load while meeting the EV swapping demand and can decrease the daily load fluctuations by 0.65% and 12.89%, reduce the peak–valley difference by 5.81% and 7.80%, and increase the load rate by 3.67% and 4.08% in working and non-working day situations through providing the dynamic dispatchable capacity for the grid.…”
    Get full text
    Get full text
    Get full text
    article
  14. 634
  15. 635
  16. 636
  17. 637
  18. 638

    Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus by Dimitrios, Patoulias

    Published 2023
    “…They have demonstrated1 that empagliflozin treatment resulted in a significant decrease in pulse pressure (PP), mean arterial pressure (MAP) and cardiac workload, compared with placebo; at week 12, placebo-adjusted mean changes from baseline were − 2.5 mmHg for PP, − 2.2 mmHg for MAP and − 315 mmHg x beats per minute (bpm) for cardiac workload (p < 0.0001 for all). …”
    Get full text
    Get full text
    Get full text
  19. 639
  20. 640